Brand Intelligence Graphcompany
Company Overview
About Boston Scientific
Boston Scientific Corporation is a Marlborough, Massachusetts-based global medical device company — publicly traded on the New York Stock Exchange (NYSE: BSX) as an S&P 500 Health Care component — developing and commercializing medical devices for minimally invasive diagnosis and treatment of cardiovascular disease, cardiac rhythm management, electrophysiology, urology, endoscopy, and neuromodulation through approximately 48,000 employees in 130 countries. In fiscal year 2024, Boston Scientific reported revenues of $16.7 billion (+18% year-over-year) — driven by the Farapulse pulsed field ablation (PFA) system for atrial fibrillation treatment, WATCHMAN FLX left atrial appendage closure (LAAC) device, and Rhythmia Ultra high-density cardiac mapping — making Boston Scientific the fastest-growing large-cap medical device company and one of the strongest organic growth stories in healthcare. CEO Mike Mahoney has executed acquisitions and organic R&D investment to build a diverse cardiovascular and electrophysiology portfolio: the 2023 acquisition of Apollo Endosurgery ($615 million, flexible endoscopic stapling for minimally invasive procedures) and the 2022 acquisition of Lumenis (surgical laser systems) expanded Boston Scientific beyond the cardiac core. Boston Scientific's strongest 2024 growth driver — Farapulse (pulsed field ablation) — achieved rapid adoption as a new standard-of-care in atrial fibrillation ablation by delivering shorter procedure times (2-hour PFA versus 4-hour radiofrequency ablation) and improved safety profile compared to traditional thermal ablation methods.
Business Model & Competitive Advantage
Boston Scientific's medical device portfolio model creates competitive advantages through the procedure-embedded clinical training and physician adoption dynamics of minimally invasive cardiac devices: an electrophysiologist who trains on Farapulse PFA at Boston Scientific's hands-on simulation lab (BSC's Electrophysiology Learning Centers in Boston, Minneapolis, and Amsterdam) becomes a trained Farapulse operator — building procedural volume on Farapulse catheters, generators, and mapping systems that create quarterly reorder revenue from the BSC distributor relationship. The WATCHMAN FLX LAAC device (implanted in the left atrial appendage to prevent stroke in atrial fibrillation patients who cannot take blood thinners) has generated over 100,000 cumulative implants globally and holds 70%+ market share in the LAAC market against the only competitor (Abbott's Amulet device) — creating dominant installed base and physician training advantage that new LAAC entrants cannot easily displace. Boston Scientific's electrophysiology portfolio depth (Rhythmia Ultra mapping, Farapulse ablation, CARTO integrated workflow with J&J collaboration, and LATITUDE remote monitoring) creates system value for hospital EP labs that select the full Boston Scientific ecosystem over piecemeal competitive device selection.
Competitive Landscape 2025–2026
In 2025, Boston Scientific competes in electrophysiology, cardiac rhythm management, and urology/endoscopy against Abbott Laboratories (NYSE: ABT, Amulet LAAC, CardioMEMS, TactiCath cardiac mapping), Medtronic (NYSE: MDT, pulsed field ablation entry with PulseSelect system, Arctic Front cardiac ablation), and Johnson & Johnson's MedTech (NYSE: JNJ, Biosense Webster CARTO mapping, Thermocool ablation catheter) for electrophysiology lab capital equipment purchases, atrial fibrillation ablation procedure volume, and LAAC device market leadership. Medtronic's PulseSelect PFA system launch in 2024 created direct competition for Farapulse in the high-growth pulsed field ablation market — requiring BSC to defend early market share through physician training scale and clinical evidence superiority. The urology segment growth (SpaceOAR hydrogel for prostate radiation protection, LithoVue single-use ureteroscope) and neuromodulation segment (Precision Montage MRI-conditional spinal cord stimulation) provide revenue diversification that balances cardiac cycle risk. The 2025 strategy focuses on Farapulse pulsed field ablation market development (global EP lab adoption, physician training at scale), WATCHMAN FLX LAAC expansion into type 2 diabetes/obesity patient risk stratification, and emerging markets cardiovascular infrastructure investment.
The Boston Scientific Story
Founders
Recent Activity
View all →Company Timeline
Major milestones in Boston Scientific's journey
Leadership Team
Meet the leaders behind Boston Scientific
Michael F. Mahoney
Mike Mahoney has served as CEO since 2012 and Chairman since 2016, leading Boston Scientific's transformation into a high-growth medical technology leader. He holds a B.B.A. in Finance from University of Iowa and an M.B.A. from Wake Forest University. Before joining Boston Scientific in 2011, Mahoney spent 12 years advancing through leadership roles at GE Medical Systems, served as President and CEO of Global Healthcare Exchange (2001-2006), and held senior positions at Johnson & Johnson (2007-2010). Under his leadership, Boston Scientific sales grew 18% to $16.7 billion in 2024. He serves on the boards of CVS Health and Boys & Girls Club of Boston.
Joseph M. Fitzgerald
Joseph Fitzgerald leads Boston Scientific's Cardiology division, the company's largest business segment generating over $10 billion in revenue. He oversees the interventional cardiology, structural heart, and cardiac rhythm management portfolios, driving innovation in treatments for coronary artery disease, heart failure, and cardiac arrhythmias.
Jonathan Monson
Jonathan Monson serves as CFO, overseeing all financial operations, strategy, and reporting for Boston Scientific. His leadership has been instrumental in the company's strong financial performance, including the 17.6% revenue growth achieved in 2024 and successful execution of major acquisitions including Axonics and Silk Road Medical.
Brad Sorenson
Brad Sorenson leads global operations for Boston Scientific, managing the company's worldwide manufacturing, supply chain, and operational excellence initiatives. He ensures the reliable delivery of life-saving medical devices to healthcare providers and patients across the globe while maintaining the highest quality standards.
Vance R. Brown
Vance Brown serves as the company's chief legal officer, overseeing all legal, compliance, regulatory, and corporate governance matters. His leadership ensures Boston Scientific navigates complex global regulatory frameworks while maintaining the highest ethical and legal standards across its operations.
Miriam O'Sullivan
Miriam O'Sullivan leads global human resources strategy for Boston Scientific's 63,000+ employee workforce. She oversees talent acquisition, development, compensation, benefits, and workplace culture initiatives that have earned the company recognition for diversity, equity, and inclusion leadership, including over 99% pay equity achievement.
Dr. Kenneth Stein
Dr. Kenneth Stein serves as Boston Scientific's chief medical officer, providing medical and scientific leadership across the company's product development, clinical research, and regulatory strategy. He ensures that medical innovation is grounded in clinical evidence and advances patient care outcomes.
Xavier Bertrand
Xavier Bertrand was appointed President of EMEA on December 1, 2024, leading Boston Scientific's operations across European, Middle Eastern, and African markets. He oversees commercial strategy, market development, and customer relationships in these critical international regions.
Stephen Morse
Stephen Morse leads Boston Scientific's Asia Pacific operations, driving growth in emerging markets where the company has achieved 9.8% year-over-year growth in Q1 2025. He oversees market expansion, regulatory affairs, and commercial operations across the diverse APAC region.
Key Differentiators
Market Leader
Boston Scientific is recognized as a market leader in the Healthcare Tech sector, demonstrating strong industry presence and customer trust.
Enterprise Scale
With $16.7B in revenue, Boston Scientific operates at enterprise scale with proven market validation.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Pfizer
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The compan
Moderna
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stép
Amgen
Amgen Inc. is one of the world's largest biotechnology companies, headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics, Amgen pioneered the development of biologic
Veeva Systems
Veeva Systems Inc. is the leading cloud software provider for the global life sciences industry, headquartered in Pleasanton, California. Founded in 2007 by Peter Gassner (a former Salesforce executiv
Doximity
Doximity is a professional network and digital health platform purpose-built for licensed physicians and other healthcare professionals in the United States. With more than two million verified clinic
Zocdoc
Zocdoc operates a two-sided marketplace connecting patients with physicians, dentists, and mental health providers who accept their specific insurance and have real-time appointment availability. Pati
Compare Boston Scientific with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Boston Scientific? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Boston Scientific Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Boston Scientific vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →